IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Britta HARDY et al

Serial No.:

10/577,679

Filed:

April 28, 2006

For:

ANGIOGENIC PEPTIDES AND USES THEREOF

Examiner:

Not yet Assigned

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: 1654

Attorney

Docket: 31831

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan

Registration No. 40,338

Dated: February 11, 2007



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE equired to respond to a collection of information unless it contains a valid OMB control number

Under the Paperw	ork Reduction	Access to a collection of the second	information unless it contains a value	OMB control number.	
Substitute for form 1449A/PTO			Complete if Known		
			Application Number	10/577,679	
INFORMATION DISCLOSURE			Filing Date	April 28, 2006	
STATEMENT BY APPLICANT (use as many sheets as necessary)			First Named Inventor	Britta HARDY et al	
			Group Art Unit	1654	
			Examiner Name	Not Yet Assigned	
Sheet	1	Of 1 Attorney Docket Number 31831		31831	
_	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner	Cite	Include name of the author (in CAPITAL LETTERS			
Initials	No.1	item (book, magazine, journal, serial symposium, ca	erial symposium, catalog, etc.) date, page(s), volume-issue number(s), isher, city and/or country where published.		
	1	Puzas "Human TRAP Peptide SEQ ID NO: 24", Database Geneseq 'Online!,			
	1.	Database Accession No. ABR44764, 2003.			
	2	Bainbridge et al. "A Peptide Encoded by Exon 6 of VEGF (EG3306) Inhibits VEGF-IncludedAngiogenesis In Vitro and Ischaemic Retinal Neovascularisation In Vivo", Biochemidal and Biophysical Research Communications, 302: 793-799, 2003.			
	3	Conway et al. "Molecular Mechanisms of Blood Vessel Growth", Cardiovascular			
		Research, 49: 507-521, 2001.			
	4	Giordano et al. "Biopanning and Rapid Analysis of Selective Interactive			
		Ligands", Nature Medicine, 11(7), 1249-1253, 2001.			
	5	Hetian et al. "A Novel Peptide Isolated from a Phage Display Library Inhibits Tumor Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth Factor to its Kinase Domain Receptor", The Journal of Biological Chemistry, 277(45): 43137-43142, 200 2.			
	6	Liu et al. "Combinataorial Peptide Library Methods for Immunobiology Research",			
		Experimental Hematology, 31: 11-30, 2003			
			<u> </u>		
					···
					·
	-				

Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

*EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Considered